Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors

World Journal of Surgery

Volumn 38, Issue 3, 2014, Pages 688-695

  Onoda, Naoyoshi ^a   Nakamura, Masanori ^a   Aomatsu, Naoki ^a   Noda, Satoru ^a   Kashiwagi, Shinichiro ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ARTICLE; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME ABERRATION; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION STUDY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; HUMANS; TAXOIDS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894667039     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-2409-7     Document Type: Article

References (32)

1. Smallridge RC (2012) Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97:2566-2572
2. Akaishi J, Sugino K, Kitagawa W et al (2011) Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21:1183-1189
3. Sugitani I, Miyauchi A, Sugino K et al (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36:1247-1254. doi: 10.1007/s00268-012-1437-z
4. Cabanillas ME, Waguespack SG, Bronstein Y et al (2010) Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595
5. Benvenga S (2011) Emerging therapies in sight for the fight against dedifferentiated thyroid cancer. J Clin Endocrinol Metab 96:347-350
6. Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684-685
7. Kebebew E, Peng M, Reiff E et al (2006) A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140:960-966 discussion 966-967
8. Reddi HV, Driscoll CB, Madde P et al (2013) Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther 20:267-275
9. Schweppe RE, Klopper JP, Korch C et al (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341
10. Ogisawa K, Onoda N, Ishikawa T et al (2002) Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase. J Surg Oncol 80:197-203
11. Seabright M (1971) A rapid banding technique for human chromosomes. Lancet 2:971-972
12. Nobuhara Y, Onoda N, Yamashita Y et al (2005) Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110-1116
13. Chung SH, Onoda N, Ishikawa T et al (2002) Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93:1358-1365
14. Tsutsui K (1995) Treatment for anaplastic carcinoma of the thyroid. Jpn J Cancer Clin 41:137-144 (in Japanese)
15. Onoda N, Aomatsu N, Nakamura M et al (2011) Basic study of anaplastic thyroid carcinoma using authentic cell lines. Endocr Surg 28:238-243 (in Japanese)
16. Liu D, Hou P, Liu Z et al (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311-7319
17. Liu J, Brown RE (2010) Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp Pathol 3:755-762
18. Knauf JA, Sartor MA, Medvedovic M et al (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3153-3162
19. Nakamura T, Yana I, Kobayashi T et al (1992) p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293-1298
20. Salvatore G, Nappi TC, Salerno P et al (2007) A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67:10148-10158
21. Kammori M, Onoda N, Nakamura K et al (2006) Specific subtelomere loss on chromosome der(11)t(3;11)(q23;q23)x2 in anaplastic thyroid cancer cell line OCUT-1. Int J Mol Med 18:9-16
22. Nappi TC, Salerno P, Zitzelsberger H et al (2009) Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69:1916-1923
23. Matsuse M, Sasaki K, Nishihara E et al (2012) Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups. PLoS One 7:e36063
24. Finn S, Smyth P, O'Regan E et al (2007) Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med 131:65-73
25. Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587-594
26. Higashiyama T, Ito Y, Hirokawa M et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7-14
27. Kawada K, Kitagawa K, Kamei S et al (2010) The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40:596-599
28. Smallridge RC, Ain KB, Asa SL et al (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104-1139
29. D'Agostino M, Voce P, Celano M et al (2012) Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22:138-144
30. Hoffmann S, Wunderlich A, Celik I et al (2006) Paneling human thyroid cancer cell lines for candidate protein for targeting anti-angiogenic therapy. J Cell Biochem 98:954-965
31. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
32. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335-2342